- Home
- QFIN vs INBX Comparison
QFIN vs INBX Comparison
Compare QFIN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QFIN | INBX |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | QFIN | INBX |
|---|---|---|
| Price | $11.60 | $102.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $22.20 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.2M | 196.7K |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $11.25 | $26.19 |
| 52 Week High | $32.69 | $155.29 |
Technical Indicators
Market Signals| Indicator | QFIN | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 28.98 | 62.37 |
| Support Level | $11.31 | $99.20 |
| Resistance Level | $14.17 | $106.40 |
| Average True Range (ATR) | 0.43 | 6.20 |
| MACD | -0.12 | 1.75 |
| Stochastic Oscillator | 12.03 | 86.65 |
Price Performance
Historical ComparisonAbout QFIN Qifu Technology Inc.
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.